Skip to main content

Table 1 Patient and tumor characteristics

From: Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

Characteristic, N (%) Arm A
N = 22
Arm B
N = 14
Arm C
N = 14
P value
Age at randomization
 18–39 years 2 (9) 5 (36) 1 (7)  
 40–49 years 8 (36) 0 5 (36)  
 50–59 years 5 (23) 4 (29) 7 (50)  
 ≥ 60 years 7 (32) 5 (36) 1 (7) 0.02
Extent of surgery
 Breast sparing 9 (41) 6 (43) 6 (43)  
 Mastectomy 13 (59) 8 (57) 8 (57) 0.99
Tumor size
 ≤ 2.0 cm 9 (41) 6 (43) 9 (64)  
 2.1–4.9 cm 13 (59) 7 (50) 5 (36)  
 ≥ 5.0 cm 0 1 (7%) 0 0.33
Axillary lymph node dissection
 Yes 20 (91) 14 (100) 14 (100)  
 No 2 (9) 0 0 0.27
Sentinel node biopsy
 Yes 8 (36) 8 (57) 6 (43)  
 No 14 (64) 6 (43) 8 (57) 0.47
Tumor grade
 Low/Intermediate 4 (18) 4 (29) 6 (43)  
 High 18 (82) 10 (71) 8 (57) 0.28
T stage
 1 9 (41) 6 (43) 9 (64)  
 2 13 (59) 7 (50) 5 (36)  
 3 0 1 (7) 0 0.33
N stage
 1 21 (95) 13 (93) 14 (100)  
 2 1 (5) 1 (7) 0 0.62